Beads were washed twice and incubated with biotinylated antibodies (25 μl/well) for 1 h. After removal of excess antibodies, streptavidin-PE was added for 30 min. The plate was then washed and analysed. The lower detection limits of the assay defined by the manufacturer were 6, 3, 5, 5 and 10 ρg/ml

for IL-2, IL-5, IL-10, IFN-γ and TNF-α, respectively. Differential counts were performed on EDTA-treated blood by using ABX Pentra 60 Hematology Analyzer (Horiba Diagnostic Ku-0059436 molecular weight Group, France). Due to logistic challenges in the laboratory, haematological analyses were only conducted on blood samples collected after 24 October 2009. Samples with an improper separation and gating of the detected cell subsets as assessed by visual inspection of the scatter plot produced by the ABX Pentra60 were repeated if sufficient amount of blood was available; poor quality analyses were excluded. From the DBSs, RBP and CRP were measured concurrently by a combined simple sandwich ELISA method [8] and [9]. The samples were tested in duplicates with the paired baseline and follow-up samples in the same assay. Samples with

a coefficient of variance >20% were repeated in duplicates. Data was analysed using STATA 12 (StataCorp LP, College Station, TX, USA). As in our previous study [4], cytokine outcomes were categorised as below versus above the median, and analysed by Poisson regression with robust estimate variance providing prevalence ratios (PR) of being above the median in OPV0 + BCG versus BCG alone recipients. The prevalence of BCG scars or local reactions was analysed by Poisson regression with robust estimate variance. BCG scar Dabrafenib nmr size was analysed by linear regression. For every plate analysed on the Luminex instrument, the range of the cytokine analysis assay was defined by the lower and upper range of the standard series after censoring for standard concentrations outside a recovery limit of 80–120% (observed concentration versus expected concentration). If the lower detection limit as defined by the manufacturer was higher than the lower limit inferred from the standard series, the

former was applied. Observations outside this range were considered as non-detectable. Cytokine outcomes with >50% detectable measurements were log-transformed and analysed with Tobit regression to account for observations Adenosine below or above the detection range of the Luminex assay [10]. The estimates were back-transformed to give the geometric mean ratios (GMR) comparing OPV0 + BCG with BCG alone. Hence, a GMR or a PR > 1 may be interpreted as OPV increasing the given outcome. Log-transformed haematological data was analysed with linear regression using bootstrap to obtain confidence intervals (CI). CRP and RBP were analysed by Poisson regression as the risk of having a CRP measurement >5 μg/ml or a RBP level <0.83 μmol/l (vitamin A-deficient [11]). RBP was log-normally distributed and analysed by linear regression.